Courtes Marie-Gabrielle, Baudoux Nathalie, Astaras Christoforos, Fernandez Eugenio
Service d'oncologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Rev Med Suisse. 2022 May 18;18(782):1002-1006. doi: 10.53738/REVMED.2022.18.782.1002.
High-dose intravenously (i.v) vitamin C in cancer patients is controversial. Numerous studies carried out on cancer cell lines and animal models demonstrated that millimolar vitamin C concentrations inhibit tumor cells viability, especially in association with chemotherapy. In cancer patients, high-dose i.v vitamin C in monotherapy does not show any anti-cancer activity. Clinical trials assessing high-dose i.v vitamin C concomitantly with chemotherapy do not conclude to reliable evidence for tumor control or overall survival benefit. Randomized double-blind trials are warranted.
癌症患者静脉注射大剂量维生素C存在争议。在癌细胞系和动物模型上进行的大量研究表明，毫摩尔浓度的维生素C会抑制肿瘤细胞的活力，尤其是与化疗联合使用时。在癌症患者中，大剂量静脉注射维生素C单一疗法未显示出任何抗癌活性。评估大剂量静脉注射维生素C与化疗同时使用的临床试验并未得出关于肿瘤控制或总生存获益的可靠证据。有必要进行随机双盲试验。
